Scientists develop probe to prevent Alzheimer’s disease
- Researchers from Rice University in Houston, Texas, developed a probe to target proteins in the brain that cause Alzheimer’s disease
- More than five million people in the US suffer from the degenerative disease
- Previous studies have used medication to attempt to target these proteins
- Experts say this probe could improve medication for the disease
Danielle Zoellner For Dailymail.com
3
View
comments
Rogue brain proteins that trigger Alzheimer’s disease could be destroyed using cheap light therapy, according to new research.
An optic probe has been developed by scientists that glows over 100 times more brightly when it identifies the fine fibers, or fibrils, of amyloid beta that kill neurons.
The light then oxidizes the fibers to prevent them from clumping together in patients’ brains, which inhibits memory and makes them confused.
An estimated five-and-a-half million people in the United States suffer from Alzheimer’s, according to the Alzheimer’s Association.
Experts say this technique could be an inexpensive way for doctors to halt the disease before it impacts the brain’s memory and cognitive function.
Researchers developed a probe to detect clumping in the brain that leads to dementia and Alzheimer’s disease. This probe uses light therapy to target the clumps in the brain
Professor Angel Marti, an associate professor of chemistry at Rice University in the Houston, Texas, and his team developed the probe because light ‘is a cheap resource.’
He said light activation allows his team to have ‘exquisite control’ of oxidation.
Professor Marti said: ‘We imagine it might be possible someday to prevent symptoms of Alzheimer’s by targeting amyloid beta in the same way we treat cholesterol in people now to prevent cardiovascular disease.’
-
Scientists uncover first PHYSICAL PROOF that living next to…
Intelligent people have a higher risk of mental illness -…
ALZHEIMER’S: FAST FACTS
WHAT IS IT?
Alzheimer’s disease is a progressive, degenerative disease of the brain.
A build-up of abnormal proteins causes nerve cells to die.
This disrupts the transmitters that carry messages, and causes the brain to shrink.
WHAT HAPPENS?
As brain cells die, the functions they provide are lost.
That includes memory, orientation and the ability to think and reason.
The progress of the disease is slow and gradual.
On average, patients live five to seven years after diagnosis, but some may live for ten to 15 years.
EARLY SYMPTOMS:
- Loss of short-term memory
- Disorientation
- Behavioral changes
- Mood swings
- Difficulties dealing with money
- Difficulties making a phone call
- Difficulties following a TV show
LATER SYMPTOMS:
- Severe memory loss, forgetting close family members, familiar objects or places
- Becoming anxious and frustrated over inability to make sense of the world…
- …This can lead to aggressive behavior
- Eventually lose ability to walk
- May have problems eating and drinking
- The majority will eventually need 24-hour care
HOW ALZHEIMER’S DIFFERS FROM NORMAL MEMORY LOSS:
With ordinary age-related forgetfulness, you will still remember details associated with the thing they’ve forgotten.
For example, you may forget your neighbor’s name in conversation, but you still know that person is your neighbor.
Alzheimer’s sufferers forget the entire context.
The clumping together of the amyloid beta is one of the main causes of dementia and Alzheimer’s, but drugs that target it have so far failed.
Build-up of the protein is one of the earliest changes seen in patients’ brains, forming sticky plaques and leading to nerve cell death and memory loss.
The probe pinpoints a specific binding site on the protein that could facilitate better drugs to treat the disease.
The device, described in the journal Chem, targets the fibrils using a rare metal called rhenium – and glows when hit with ultraviolet light.
But when it binds to the toxic protein it becomes more than 100 times brighter – causing it to oxidize.
‘While we cannot see the rhenium complex we can find the oxidation, or footprint, it produces on the amyloid peptide,’ Professor Marti said.
‘That oxidation only happens right next to the place where it binds. The real importance of this research is that it allows us to see with a high degree of certainty where molecules can interact with amyloid beta fibrils.’
Alzheimer’s is a degenerative brain disease that affects more than five million people living in the United States.
The symptoms can progress slow or gradual depending on the type of disease.
As the brain cells die in the brain, it causes memory loss and disorientation.
Previous research has studied the use of medication to target the fibrils in the brain that clump because of the disease.
But these medications have had difficulty targeting areas where the clumps occur.
Professor Marti said this device could help solve that problem.
‘There’s an interest in finding medications that will quench the deleterious effects of amyloid beta aggregates,’ Professor Marti said.
‘But to create drugs for these, we first need to know how drugs or molecules in general can bind and interact with these fibrils, and this was not well known.
‘Now we have a better idea of what the molecule needs to interact with these fibrils.’
He said the findings are important for the design of new drugs targeting amyloid beta.
If the resulting oxidation keeps the fibrils from aggregating further into the sticky substance found in the brains of Alzheimer’s patients, it offers hope of an effective treatment.
‘If we can modify complexes so they absorb red light, which is transparent to tissue, we might be able to perform these photochemical modifications in living animals, and maybe someday in humans,’ Professor Marti said.
Share or comment on this article
- ‘Blood and human flesh were spattered everywhere’: ISIS…
- More than 50 Egyptian police and conscripts are killed…
- Boy with rare skin condition gets to live his dream of…
- Why bed is now the last place we wear our pyjamas: Sleep…
- Top theatre director, 76, is ‘ousted’ over lewd comments…
- Two hundred exhausted migrants – including dozens of…
- This is Britain: Striking photos of lakes, cornfields and…
- Millions of shoppers are depriving charities of thousands…
- ANGELA EPSTEIN: Why row over anti-Semitism claims in the…
- Inspiring story of care home couple who fought to stay…
- Police probe 800 Britons suspected of making false food…
- Is this the cell where British jihadi who quit his job at…
- Caught on CCTV: Rapist forced innocent schoolgirl into…
- Man is arrested over shocking video of woman being kicked…
- They blew the bloody neighbours up, too! Italian Job…
- ‘I feel sad but I’m going to be brave’: Eight-year-old…
- Corbyn-supporting ‘intellectual’ journalist, 27, who has…
- Cambridge dons are told to register affairs with…
Comments 3
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
Close
Do you want to automatically post your MailOnline comments to your Facebook Timeline?
Your comment will be posted to MailOnline as usual.
Close
Do you want to automatically post your MailOnline comments to your Facebook Timeline?
Your comment will be posted to MailOnline as usual
We will automatically post your comment and a link to the news story to your Facebook timeline at the same time it is posted on MailOnline. To do this we will link your MailOnline account with your Facebook account. We’ll ask you to confirm this for your first post to Facebook.
You can choose on each post whether you would like it to be posted to Facebook. Your details from Facebook will be used to provide you with tailored content, marketing and ads in line with our Privacy Policy.